Education
About Us
Working with TipRanks
Follow Us
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Total Valuation
Inhibikase Therapeutics has a market cap or net worth of $156.86M. The enterprise value is $127.99M.
Market Cap$156.86M
Enterprise Value$127.99M
Share Statistics
Inhibikase Therapeutics has 74,341,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding74,341,540
Owned by Insiders9.83%
Owned by Institutions61.65%
Financial Efficiency
Inhibikase Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -30.10%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.28
Return on Invested Capital (ROIC)-30.10%
Return on Capital Employed (ROCE)-0.30
Revenue Per Employee0.00
Profits Per Employee-1.83M
Employee Count15
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inhibikase Therapeutics is -2.80. Inhibikase Therapeutics’s PEG ratio is 0.04.
PE Ratio-2.80
PS Ratio812.56
PB Ratio0.81
Price to Fair Value0.81
Price to FCF-4.02
Price to Operating Cash Flow-4.02
PEG Ratio0.04
Income Statement
In the last 12 months, Inhibikase Therapeutics had revenue of 0.00 and earned -27.52M in profits. Earnings per share was -1.16.
Revenue0.00
Gross Profit0.00
Operating Income-28.59M
Pretax Income-27.52M
Net Income-27.52M
EBITDA-28.59M
Earnings Per Share (EPS)-1.16
Cash Flow
In the last 12 months, operating cash flow was -17.24M and capital expenditures 14.24K, giving a free cash flow of -17.23M billion.
Operating Cash Flow-17.24M
Free Cash Flow-17.23M
Free Cash Flow per Share-0.23
Dividends & Yields
Inhibikase Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.69
52-Week Price Change32.70%
50-Day Moving Average2.23
200-Day Moving Average2.12
Relative Strength Index (RSI)50.89
Average Volume (3m)138.10K
Important Dates
Inhibikase Therapeutics upcoming earnings date is May 19, 2025, TBA Not Confirmed.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Inhibikase Therapeutics as a current ratio of 26.37, with Debt / Equity ratio of -27.37%
Current Ratio26.37
Quick Ratio26.37
Debt to Market Cap<0.01
Net Debt to EBITDA1.97
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Inhibikase Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Inhibikase Therapeutics EV to EBITDA ratio is -0.72, with an EV/FCF ratio of -1.08.
EV to Sales0.00
EV to EBITDA-0.72
EV to Free Cash Flow-1.08
EV to Operating Cash Flow-1.08
Balance Sheet
Inhibikase Therapeutics has $3.24M in cash and marketable securities with $209.49K in debt, giving a net cash position of -$3.10M billion.
Cash & Marketable Securities$3.24M
Total Debt$209.49K
Net Cash-$3.10M
Net Cash Per Share-$0.04
Tangible Book Value Per Share$4.00
Margins
Gross margin is -1970400.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-1970400.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Inhibikase Therapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$8.00
Price Target Upside279.15% Upside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast-100.00%
EPS Growth Forecast38.72%